Literature DB >> 6313220

Transcriptional activation of cloned human beta-globin genes by viral immediate-early gene products.

M R Green, R Treisman, T Maniatis.   

Abstract

When the human beta-globin gene is transfected into Hela cells, no beta-globin RNA is detected unless the gene is linked to a viral transcription enhancer. In this paper we show that trans-acting adenovirus and herpesvirus (pseudorabies) transcriptional regulatory proteins can circumvent this enhancer requirement for detectable beta-globin transcription in transient expression assays. The viral gene products can be provided by constitutively expressed, integrated viral genes in established cell lines, by viral infection of permissive cells, or by transfection of cells with bacterial plasmids carrying the viral immediate-early genes. These results demonstrate the utility of transient expression assays for studying regulatory mechanisms involving trans-acting factors. Analysis of beta-globin promoter mutants indicates that between 75 and 128 bp of sequence 5' to the mRNA cap site is required for enhancer-dependent transcription in Hela cells. In contrast, beta-globin transcription in the presence of viral immediate-early gene products requires only 36 bp of 5'-flanking sequence, which includes the TATA box. Thus both cis and trans-acting viral factors activate beta-globin gene transcription in transient expression experiments, but the mechanisms by which they act appear to be fundamentally different.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313220     DOI: 10.1016/0092-8674(83)90216-7

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  179 in total

1.  Activation of the human epsilon- and beta-globin promoters by SV40 T antigen.

Authors:  S X Cao; H Mishoe; J Elion; P E Berg; A N Schechter
Journal:  Biochem J       Date:  1989-03-15       Impact factor: 3.857

2.  Subnuclear localization of the trans-activating protein of human T-cell leukemia virus type I.

Authors:  D J Slamon; W J Boyle; D E Keith; M F Press; D W Golde; L M Souza
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Transcriptional trans-activating function of hepatitis B virus.

Authors:  J S Twu; R H Schloemer
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

4.  trans-activation of viral enhancers by the hepatitis B virus X protein.

Authors:  D F Spandau; C H Lee
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

5.  Phosphorylation in vitro of Escherichia coli-produced 235R and 266R tumor antigens encoded by human adenovirus type 12 early transformation region 1A.

Authors:  L A Lucher; P M Loewenstein; M Green
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

6.  Nucleotide sequence of the pseudorabies virus immediate early gene, encoding a strong transactivator protein.

Authors:  C Vlcek; V Paces; M Schwyzer
Journal:  Virus Genes       Date:  1989-08       Impact factor: 2.332

7.  Individual adenovirus type 5 early region 1A gene products elicit distinct alterations of cellular morphology and gene expression.

Authors:  B E Roberts; J S Miller; D Kimelman; C L Cepko; I R Lemischka; R C Mulligan
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

8.  Synthesis in Escherichia coli of human adenovirus type 12 transforming proteins encoded by early region 1A 13S mRNA and 12S mRNA.

Authors:  D Kimelman; L A Lucher; K H Brackmann; J S Symington; M Ptashne; M Green
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

9.  Identification of adenovirus 12-encoded E1A tumor antigens synthesized in infected and transformed mammalian cells and in Escherichia coli.

Authors:  L A Lucher; D Kimelman; J S Symington; K H Brackmann; M A Cartas; H Thornton; M Green
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

10.  Complementary functions of E1a conserved region 1 cooperate with conserved region 3 to activate adenovirus serotype 5 early promoters.

Authors:  H K Wong; E B Ziff
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.